Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876, it discovers, develops, manufactures, and markets human medicines, with a focus on therapeutic areas including diabetes, oncology, immunology, and neuroscience. The company also maintains an expanding presence in infectious disease prevention through vaccine development.
chemXplore tracks 3 projects involving Eli Lilly and Company, of which 2 are active.
Eli Lilly and Company's role on them: Owner, Investor / Financier, Operator, and Developer.
1 new construction and 1 expansion.
Expected to start operating, per year.
Contractors are recorded on all 2 of them For subscribers
Targeting: Orforglipron (2), Retatrutide (1), Tirzepatide (1)
FDA clears once‑weekly basal insulin that reduces injection frequency vs daily therapy; Phase 3 QWINT trials in >3,400 adults showed non‑inferior A1C vs glargine and degludec.
New $6.5B Houston plant will make APIs including Foundayo, create 600+ high-wage jobs, and fund $12.5M for workforce training with San Jacinto College.
FDA grants full approval to the all‑oral imlunestrant + abemaciclib combination for adults with ER+, HER2–, ESR1‑mutated advanced or metastatic breast cancer after prior endocrine therapy.
Phase 3 retatrutide and Foundayo results show large weight and A1C reductions and signals of cardiovascular benefit; Phase 2 eloraTZP and additional Mounjaro/Zepbound analyses also presented.
Adds clinical-stage neuroplastogens, including lead program BPL-003 for treatment‑resistant depression; transaction approved by AtaiBeckley shareholders.
Precision platform targets pathogenic autoantibodies; MER511 Phase 1 shows strong reductions in thyroid‑stimulating antibodies; deal includes up to $2.875B in cash.
Combination maintained or deepened psoriasis and psoriatic arthritis responses and reduced systemic inflammation while improving metabolic measures including BMI and HbA1c at one year versus Taltz alone.
First GIP+GLP‑1 agonist authorised to lower major adverse cardiovascular events in high‑risk adults with type 2 diabetes; SURPASS‑CVOT enrolled >13,000 with ~4‑year median follow‑up.
By country, the most active first.
